Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Jacqueline Bosch"'
Autor:
Jacqueline Bosch, PhD, Paul Moayyedi, MD, PhD, Marco Alings, MD, PhD, Alvaro Avezum, Jr., MD, PhD, Shrikant I. Bangdiwala, PhD, Alan Barkun, MD, CM, MSc, Federico Cassella, MD, Aloisio Marchi da Rocha, MD, PhD, Irfan Duzen, MD, Robert Enns, MD, Nauzer Forbes, MD, MSc, Leah Hamilton, MSc, Shofiqul Islam, PhD, Mustafa Kilickap, MD, MSc, Paul Kruger, MBBS, Yan Liang, MD, Jose C. Nicolau, MD, Rafael Nunes, MD, PhD, Martin O’Donnell, MD, PhD, Gustavo Oliveira, MD, PhD, Alejandro Rey, MD, Yihong Sun, MD, Thomas Vanassche, MD, Peter Verhamme, MD, Michael Walsh, MD, PhD, Zhenyu Wang, MD, Cynthia Wu, MD, Li Zhao, MD, Jun Zhu, MD, John W. Eikelboom, MBBS
Publikováno v:
CJC Open, Vol 4, Iss 11, Pp 996-1005 (2022)
Background: Bleeding is the most common adverse event in those with cardiovascular (CV) disease receiving antithrombotic therapy, and it most commonly occurs in the gastrointestinal (GI) tract. Clinicians often dismiss bleeding as an adverse event th
Externí odkaz:
https://doaj.org/article/a3549bb6b92f4bf4a92465d7fd5f018b
Autor:
Noel Chan, Matt Wheeler, Vinai Bhagirath, Jacqueline Bosch, Jutta Heinrich-Nols, Debbie Sloane, Joanne van Ryn, Linda Jefferies, Jacqueline Wilkinson, Qilong Yi, John Eikelboom
Publikováno v:
CJC Open. 5:1-7
Autor:
Scott D. Berkowitz, John W. Eikelboom, Victor Aboyans, Petr Widimsky, Stuart J. Connolly, Eva Muehlhofer, Gilles R. Dagenais, Salim Yusuf, Keith A.A. Fox, Leanne Dyal, Deepak L. Bhatt, Jeffrey L. Probstfield, Bernhard R Winkelmann, Jacqueline Bosch, Darryl P. Leong
Publikováno v:
Heart
ObjectiveIn patients with chronic coronary or peripheral artery disease enrolled in the Cardiovascular Outcomes for People Using Anticoagulation Strategies trial, randomised antithrombotic treatments were stopped after a median follow-up of 23 months
Autor:
Nana Pogosova, Jacqueline Bosch, Deepak L. Bhatt, Keith A.A. Fox, Stuart J. Connolly, Marco Alings, Peter Verhamme, Eva Muehlhofer, Olga Shestakovska, Salim Yusuf, John W. Eikelboom
Publikováno v:
Circulation. 145(25)
Autor:
Dragos Vinereanu, Georg Ertl, Stefan Störk, Deepak L. Bhatt, Nana Pogosova, John Varigos, Aldo P. Maggioni, Yan Liang, Andrew Tonkin, Stuart J. Connolly, Lars Rydén, Amparo Casanova, Jacqueline Bosch, Alvaro Avezum, Kelley R. Branch, Leanne Dyal, Rafael Diaz, Kevin W Reeh, Robert G. Hart, Keith A.A. Fox, Katalin Keltai, Patricio Lopez-Jaramillo, Mukul Sharma, Martin O'Donnell, Matyas Keltai, Eva Lonn, Lisheng Liu, Jun Zhu, Jeffrey L. Probstfield, Gilles R. Dagenais, Leopoldo S. Piegas, Scott D. Berkowitz, Salim Yusuf, Eric E. Smith, John W. Eikelboom, Jae-Hyung Kim
Publikováno v:
Stroke. 51:2901-2909
Background and Purpose: Covert brain infarcts are associated with cognitive decline. It is not known whether therapies that prevent symptomatic stroke prevent covert infarcts. COMPASS compared rivaroxaban with and without aspirin with aspirin for the
Autor:
Eva Muehlhofer, Deepak L. Bhatt, Robert G. Hart, Mukul Sharma, Alvaro Avezum, Sonia S. Anand, Stuart J. Connolly, Jacqueline Bosch, Camilo Felix, Scott D. Berkowitz, Gilles R. Dagenais, Keith A.A. Fox, Tomasz J. Guzik, Olga Shestakovska, Kelley R. Branch, Aldo P. Maggioni, John W. Eikelboom, Salim Yusuf
Publikováno v:
Journal of the American College of Cardiology. 78(1)
Background The combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin once daily compared with 100 mg aspirin once daily reduces major adverse cardiovascular (CV) events in patients with chronic coronary artery disease (CAD) or peripheral a
Autor:
John W. Eikelboom, Olga Shestakovska, Eva Muehlhofer, Darryl P. Leong, Jacqueline Bosch, Thomas Vanassche, K.A.A Fox, Salim Yusuf, Peter Verhamme, Deepak L. Bhatt, Stuart J. Connolly, A.P. Maggioni
Publikováno v:
European Heart Journal. 41
Background In patients with coronary or peripheral artery disease, intensified antithrombotic therapy with aspirin plus low dose rivaroxaban reduced cardiovascular outcomes compared with aspirin alone. Polypharmacy and multimorbidity are frequent in
Publikováno v:
European Heart Journal. 40
Background Patients with coronary artery disease (CAD) and peripheral artery disease (PAD) are at high risk for cardiovascular death and ischemic events. Secondary prevention requires both optimal control of modifiable cardiovascular risk factors and
Autor:
Deepak L. Bhatt, Lars Rydén, Camilo Felix, Martin O'Donnell, Aldo P. Maggioni, Marco Alings, Victor Aboyans, Keith A.A. Fox, Scott D. Berkowitz, Jacqueline Bosch, Robert G. Hart, Peter Verhamme, Paul Moayyedi, Alvaro Avezum, Olga Shestakovska, Stuart J. Connolly, Nancy Cook-Bruns, Jun Zhu, John W. Eikelboom, Sonia S. Anand, Salim Yusuf, Petr Widimsky
Publikováno v:
Circulation. 140(18)
Background: Patients treated with antithrombotic drugs are at risk of bleeding. Bleeding may be the first manifestation of underlying cancer. Methods: We examined new cancers diagnosed in relation to gastrointestinal or genitourinary bleeding among p
Autor:
John A. Cairns, Darryl P. Leong, Olga Shestakovska, Martin O'Donnell, Stuart J. Connolly, Nancy Cook Bruns, John W. Eikelboom, Robert G. Hart, Jacqueline Bosch, Eva Muehlhofer, Salim Yusuf, Gilles R. Dagenais, Keith A.A. Fox, Aldo P. Maggioni, Rafael Diaz, Christoph Tasto, Scott D. Berkowitz, Deepak L. Bhatt
Publikováno v:
Journal of the American College of Cardiology. 74(12)
In patients with coronary or peripheral artery disease, the combination of rivaroxaban 2.5 mg twice daily and aspirin 100 mg once daily compared with aspirin 100 mg once daily reduced major adverse cardiovascular events and mortality and increased bl